ライフサイエンスコーパス: approve

1 submitted to FDA and plague indications were approved.

2 lity by increasing bone formation, have been approved.

3 The FDA approved 355 new drugs and biologics over the study peri

4 composed of US Food and Drug Administration-approved 500nm carboxylated-poly(lactic-co-glycolic) aci

5 the Organ Procurement and Transplant Network approved a plan to allocate kidneys within 250-nm circle

6 ering FcgammaRIIIa, including the clinically approved Ab cetuximab.

7 ity for the United Network for Organ Sharing-approved AC and the existing donor service area-/region-

8 the profiles of the corresponding clinically approved ADC Kadcyla.

9 The currently approved adjuvant ipilimumab dose (ipi10) was more toxic

10 Currently, there are no approved adjuvants capable of driving a Th17 response in

11 ne green (ICG) is the most commonly used FDA-approved agent for clinical optical imaging, administere

12 This article provides an overview of already approved agents as well as those on the horizon.

13 The CPGC reviews and approves all ASCO guideline products on behalf of ASCO.

14 ctive inhibitors, including the recently FDA-approved alpelisib.

15 f perampanel, a Food and Drug Administration-approved AMPA receptor (AMPAR) antagonist, during a foll

16 ntibodies targeting IL-17 pathways have been approved and are used as first line treatment of moderat

17 We also review approved and clinical-stage intratumoral therapies and c

18 ut it is not US Food and Drug Administration approved and currently is being tested in ongoing random

19 segments are US Food and Drug Administration approved and provide benefits of platinum chains with th

20 While many investigational, approved, and repurposed drugs have been suggested as po

21 her existing US Food and Drug Administration-approved anti-cancer modalities.

22 At this time, only one FDA-approved anti-SARS-CoV-2 antiviral drug, remdesivir, is

23 ced to 23% with median development times for approved antibacterial drugs increasing to 8.2 years.

24 ilzomib are two Food and Drug Administration-approved anticancer drugs, and proteasome is the drug ta

25 The approved antifibrinolytic agents such as tranexamic acid

26 predicted highly divergent MoAs for two FDA-approved antihistamines.

27 Here, we investigate how the FDA-approved antihypertensive drug, guanabenz, which has a f

28 results demonstrate that ivermectin, an FDA-approved antiparasitic agent, is effective at inhibiting

29 e option of using at least one fully active, approved antiretroviral drug in at least one but no more

30 worldwide; yet currently, no vaccines or FDA-approved antiviral drugs are available to counter these

31 Currently, there are no approved antiviral therapeutics against either Kunjin or

32 Without approved antiviral therapeutics or vaccines to this ongo

33 k for developing severe disease; however, no approved antiviral therapies specific to HAdV exist.

34 However, approved antiviral treatments such as remdesivir and rec

35 blockade-based combination therapy has been approved as a first-line treatment for head and neck squ

36 afenamide-emtricitabine (F/TAF) was recently approved as a noninferior and potentially safer option t

37 (TRD) in 2019, almost 50 years after it was approved as an intravenous anesthetic.

38 US, the EU, and Japan, S6821 and S7958 were approved as safe under conditions of intended use as bit

39 discuss other IL-1 inhibitors, not currently approved, as well as oral NLRP3 inflammasome inhibitors

40 The only approved AVP receptor agonist, desmopressin is indicated

41 ution X-ray crystallography and the recently approved beta-lactamase inhibitor avibactam to trap the

42 l. report that chronic administration of the approved beta3 agonist mirabegron to human subjects was

43 sequent labels of all vaccines that were FDA-approved between 1 January 1996 and 31 December 2015.

44 We repurposed the FDA-approved bile acid sequestrant cholestyramine, which we

45 icals Ltd, Ahmedabad, GJ, India) is the only approved biosimilar for ophthalmic use, but the landscap

46 has been previously established for the FDA-approved bispecific T cell engager, blinatumomab, for ac

47 Adalimumab is the only treatment approved by either the European Medicines Agency or the

48 ne kinase inhibitors have been developed and approved by Food and Drug Administration for the treatme

49 ted in clinical trials, and none of them are approved by health agencies.

50 In the absence of drugs approved by regulatory agencies, the current standard of

51 Paediatric dolutegravir doses approved by stringent regulatory authorities (SRAs) for

52 This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates

53 7 and 2020, 33 biosimilars for oncology were approved by the European Medicines Agency (EMA), 16 by t

54 The most common biomarker approved by the FDA (United States Food and Drug Adminis

55 nction with an oral antidepressant, has been approved by the FDA for treating treatment-resistant maj

56 s a list of all drug products that have been approved by the FDA for use in veterinary medicine.

57 ns of benzenoid rings in small molecule APIs approved by the FDA through 2019 and show that only a fe

58 Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration for relapse

59 oligonucleotide drugs that have already been approved by the Food and Drug Administration for targeti

60 Conversely, the iStent, approved by the Food and Drug Administration in 2012, in

61 The study was approved by the institutional review board and is Health

62 Health Workers Cohort Study (HWCS) has been approved by the Institutional Review Board of the Mexica

63 Our research was approved by the McGill institutional review board (A04-M

64 given once daily 25 mg film-coated tablets (approved by the SRAs at the time of the study) in part o

65 ses of 25 mg or 35 mg once daily, which were approved by the SRAs for the children's weight band; the

66 Only about two dozen formulations have been approved by the U.S. Food and Drug Administration during

67 ve brain stimulation treatment that has been approved by the U.S. Food and Drug Administration for tr

68 Both treatments are approved by the US Food and Drug Administration (FDA) fo

69 s of biotherapeutics have been developed and approved by the US Food and Drug Administration (FDA) fo

70 tial indications for adult cancers that were approved by the US Food and Drug Administration between

71 There are 3 therapies approved by the US Food and Drug Administration for mana

72 high-throughput screen to identify compounds approved by the US Food and Drug Administration that red

73 20, no treatment for food allergies had been approved by the US Food and Drug Administration.

74 l clinical trials linked to contemporary FDA-approved cancer drugs, reported CVD event rates trail ex

75 PCR was negative in all 45 committee-approved cases.

76 trinsic or acquired resistance to clinically approved CDK4/6 inhibitors has emerged as a major obstac

77 roblems, including the lack of available FDA-approved/cleared tests, limited uptake of international

78 , these two innovative methods have not been approved clinically, they have been recalculated in this

79 We screened repo>Dube3a flies for approved compounds that can suppress seizures.

80 r exhausted or were considered unfit for all approved conventional treatments.

81 the majority of clinical candidates and FDA approved covalent therapies.

82 the BMP concentration and release rate from approved CS carriers is difficult to control with precis

83 Recently, Food and Drug Administration-approved cystic fibrosis protein trafficking chaperone,

84 The FDA-approved DNA hypomethylating agents (DHAs) like 5-azacyt

85 donors and a similar likelihood of having an approved donor among African Americans compared with Cau

86 dose (RP2D, primary outcome) is the FDA/EMEA approved dose of gemcitabine-nab-paclitaxel along-with A

87 ngle dose of fluconazole 150 mg (current FDA-approved dose to treat acute VVC).

88 ed to the Food and Drug Administration (FDA)-approved drug fluoxetine-which also targets 2C-but has f

89 nib, a US Food and Drug Administration (FDA)-approved drug for leukemia, indicates improvement in Alz

90 key structural elements of darunavir, an FDA-approved drug for the treatment of HIV/AIDS.

91 ibition of TRPM7 channel activity by the FDA-approved drug FTY720 increased the sensitivity of T cell

92 The FDA-approved drug rapamycin slows aging and extends lifespan

93 Disulfiram (DSF) is an FDA-approved drug that has been repurposed for cancer treatm

94 luate how far away we are from the first FDA-approved drug therapy for mitochondrial disease.

95 ects a quarter of the population, and has no approved drug therapy.

96 icacy of auranofin (rheumatoid arthritis FDA-approved drug) in a CDI mouse model and establish an ade

97 study, an Food and Drug Administration (FDA)-approved drug, diflunisal, was found to competitively in

98 Importantly, we identified two FDA-approved drugs able to ameliorate these phenotypes.

99 ling assays, we assembled a library of 1,008 approved drugs and well-characterized tool compounds man

100 s previously identified from a screen of FDA-approved drugs as a potent EBOV viral entry inhibitor, v

101 tive analysis of known SA complexes with FDA-approved drugs clearly shows that multiple medications c

102 MAO-A with phenelzine or clorgyline, the FDA-approved drugs for antidepression, resensitize the Enz r

103 Here, we screen a library of 2024 FDA-approved drugs or drug candidates, revealing UMI-77 as a

104 posing existing Food and Drug Administration-approved drugs that inhibit viral entry, endocytosis, ge

105 d to the initiation of clinical trials using approved drugs that target the generation (ACEIs) and ac

106 medicinally relevant compounds, ranging from approved drugs to recent medicinal chemistry development

107 Forty patients received PAH-approved drugs with a significant improvement in functio

108 Additionally, two currently FDA approved drugs, afatinib and palbociclib (EGFR and CDK4/

109 nse to pulmonary arterial hypertension (PAH)-approved drugs, and transplant-free survival of patients

110 Modification of approved drugs, facile cleavage of the benzazole auxilia

111 As Food and Drug Administration-approved drugs, the tetracyclines could be quickly trans

112 enhancing RAI therapy in patients using FDA-approved drugs.

113 upportive therapies and off-label use of FDA-approved drugs.

114 n of biomolecules, including many clinically approved drugs.

115 rms) trials were pooled, yielding only three approved drugs.

116 super pathogens that do not respond to most approved drugs.

117 ial drug candidates targeting RdRp from 1906 approved drugs.

118 There are currently few approved effective treatments for SARS-CoV-2, the virus

119 2019, the U.S. Food and Drug Administration approved expanding the indication for transcatheter aort

120 DVS added 18 new WIC-approved foods to become an authorized vendor.

121 de is one of the only anti-arrhythmic agents approved for atrial fibrillation (AF) in patients with r

122 PI3Kdelta inhibitors have been approved for B-cell malignancies like CLL, small lymphoc

123 idge this gap, but few such assays have been approved for cancer applications.

124 able IL-1 inhibitors, although not currently approved for cardiovascular indications, and discuss oth

125 forts, RXR ligands (rexinoids) have not been approved for clinical trials to treat metabolic syndrome

126 n small molecules have been incorporated and approved for clinical use in PLGA-based formulations.

127 eutics, with eight ADCs and two immunotoxins approved for clinical use.

128 ype capsids, AAV1, AAV2, and AAV9, have been approved for commercial use in patients, but they may no

129 Several countries have been approved for Gavi support to introduce TCV in 2019-2020.

130 Numerous drugs are already approved for human use, and subsequently, there is a goo

131 Although some formulations are already approved for human use, more radiopharmaceuticals will e

132 ntly, no nanoparticle-based product has been approved for intraperitoneal delivery.

133 Impella was approved for mechanical circulatory support (MCS) in 200

134 these toxins, BoNT/B is one of the two types approved for medical and cosmetic uses.

135 -class bicyclic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment.

136 ant addition to care, but currently none are approved for NASH.

137 implantable pulmonary artery (PA) sensor is approved for patients with New York Heart Association Cl

138 acid (DNA) terminase inhibitor, was recently approved for prophylaxis of CMV infection in adult CMV-s

139 The expansion of immunotherapies approved for RCCs has generated a search for biomarkers

140 Although pembrolizumab is approved for recurrent/metastatic head and neck squamous

141 use for NSCLC; there is no drug specifically approved for the osimertinib-resistant BMs of NSCLC yet.

142 viral terminase complex inhibitor, has been approved for the prevention of cytomegalovirus (CMV) inf

143 potassium channels (K(V)1 family) clinically approved for the symptomatic treatment of patients with

144 still only one therapeutic anti-IgE antibody approved for the treatment of allergic conditions.

145 Ruxolitinib was recently approved for the treatment of corticosteroid-refractory

146 cytidine and 5-aza-2-deoxycytidine have been approved for the treatment of different types of hematol

147 ceptor in drug-resistant tumors and has been approved for the treatment of hormone-receptor-positive

148 emaciclib and ribociclib) that are currently approved for the treatment of patients with breast cance

149 inhibition by a monoclonal antibody has been approved for the treatment of postmenopausal osteoporosi

150 necrosis factor alpha that has already been approved for the treatment of several autoimmune conditi

151 rug that is not Food and Drug Administration-approved for their age.

152 few drugs targeting nucleic acid sensors are approved for therapeutic use.

153 Baloxavir marboxil, 4, is approved for treating influenza virus infections.

154 isms of amyloid formation, therapies are now approved for treatment of ATTR-CM.

155 PARP inhibitors are approved for treatment of cancers with BRCA1 or BRCA2 de

156 rter 2 inhibitors (SGLT2i), a new drug class approved for treatment of diabetes, have been shown to p

157 nt isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myel

158 Although ISA has been approved for treatment of invasive Aspergillus and mucor

159 lated kinase (ERK) (MEK) 1/2, which has been approved for treatment of metastatic melanoma and anapla

160 glutide is a GLP-1 receptor agonist recently approved for Type-II diabetes (T2D) treatment with super

161 start all new systemic anticancer treatments approved for use in England since 2016.

162 Nevertheless, before a new MRI device is approved for use, it is necessary to calibrate it proper

163 te analysis in GBM models, we found that FDA-approved global (panobinostat, vorinostat) and selective

164 We demonstrate that treatment with FDA-approved HCQ leads to decreased muscle fibrosis and incr

165 In comparison, daclatasvir, an approved HCV drug, suppressed more than 3 log of viraemi

166 Currently, all four FDA-approved HDAC-targeting drugs are nonselective, pan-HDAC

167 Currently, the only approved hepatitis C virus (HCV) treatment for children

168 we summarize the development and testing of approved histology-agnostic therapeutic agents and prese

169 We now show that the FDA-approved histone deacetylase inhibitor (HDACi) valproic

170 experiments (DOEs) using three different FDA-approved human inhaler devices followed by interaction p

171 Given that DMF is an approved human therapeutic drug, our findings support a

172 cts and active pharmaceutical ingredients of approved human therapeutics.

173 In Europe and the US, they are only approved if they are bioequivalent to the respective ori

174 nra, a US Food and Drug Administration (FDA)-approved IL-1R antagonist; or parthenolide, a caspase-1

175 ial chemoembolization (cTACE) is a guideline-approved image-guided therapy option for liver cancer us

176 of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lun

177 Fingolimod (FTY720), an FDA-approved immunomodulatory drug for treating multiple scl

178 rysanthemi ASNase (Erwinia) substitution was approved in 2011 for allergic reactions.

179 Baloxavir marboxil (BXM) was approved in 2018 for treating influenza A and B virus in

180 ibitors, are US Food and Drug Administration-approved in a few autoimmune/inflammatory disorders and

181 eucel and axicabtagene ciloleucel, have been approved in Europe and the USA, as well as several other

182 ammonia similarly to carglumic acid, a drug approved in Europe for the treatment of hyperammonemia d

183 ightly over half (51%) of vet drugs are also approved in human medicine.

184 iponimod, which targets S1PR1 and S1PR5, was approved in March, 2019, by the US Food and Drug Adminis

185 We also provide proof-of-principle that FDA-approved inhibitors with activity against MEKK2 can amel

186 lected the U.S. Food and Drug Administration-approved instructions for use (enrollment criteria plus

187 targeting yaws and trachoma, with the newly approved ivermectin, albendazole, diethylcarbamazine (ID

188 In addition, nilotinib, an FDA-approved kinase inhibitor that preferentially binds p38b

189 (2) Tested combinations of approved kinase inhibitors already being individually ev

190 These data indicate that repurposing the FDA-approved leukemia drug, nilotinib, may be effective for

191 magnitude more than that induced by the FDA-approved lipid nanoparticle material MC3 in vaccinated m

192 a progressive biliary tract disease without approved medical therapy, is not well understood.

193 ia (BA) is a pediatric liver disease with no approved medical therapy.

194 There are currently no FDA-approved medications to reduce cocaine relapse.

195 Here, we use the clinically approved MEK inhibitor Trametinib to investigate its pot

196 CellSearch, the only FDA-approved method for the CTC-based cancer prognosis, reli

197 control measure, however, there is no single approved method.

198 of the 48 approved NDAs were for previously approved moieties, analysis of available NDAs for refere

199 nical safety trials have the potential to be approved more quickly than de novo discovered medicines

200 In an institutional review board-approved multicenter study, we carried out a retrospecti

201 s current dataset has been made available to approved MVP researchers for genome-wide association stu

202 obtained from our institutional review board-approved myeloma database.

203 Although all but 1 of the 48 approved NDAs were for previously approved moieties, ana

204 regulations (1962-2018) and FDA databases of approved new drugs (1984-2018), generic drugs (1970-2018

205 xically object to experiments even when they approve of implementing either condition for everyone.

206 How likely is it that someone would approve of using a nuclear weapon to kill millions of en

207 Seventeen (81%) of these products were approved on the basis of designs that excluded patients

208 We used HeLa cells and screened 231 FDA-approved oncology and natural substance drugs included i

209 To confirm this role, we screened the NIH Approved Oncology collection for chemical-genetic intera

210 uct set III library and 7 compounds from the approved oncology drugs set V library were found to exhi

211 Between 1997 and 2018, the FDA approved opioids on the basis of pivotal trials of short

212 The analysis was limited to approved opioids.

213 icly available databases, we curated 883 FDA approved or investigational stage small molecule cancer

214 d in human psoriasis using vorapaxar, an FDA-approved PAR1 antagonist, on explanted lesional skin fro

215 the off-target kinase landscape of four FDA-approved PARP drugs.

216 Here, we found that olaparib, a FDA-approved PARP inhibitor, could enhance the cytotoxicity

217 Furthermore, clinically approved PCSK9-neutralizing antibodies synergize with an

218 hat for the now Food and Drug Administration-approved peanut OIT product Palforzia (Aimmune Therapeut

219 ints that can be addressed with existing FDA-approved pharmaceuticals.

220 There are no approved pharmacologic therapies to lower lipoprotein(a)

221 Currently, no approved pharmacological intervention can acutely lower

222 Despite the clinical success of approved photosensitizers (PSs), their application is so

223 d cells, the cells were treated with the FDA-approved poloxamer 188 (P188).

224 tibiotic ciprofloxacin hydrochloride and FDA-approved polymers are fabricated.

225 ections with human coronaviruses are not yet approved, posing a serious challenge to current global e

226 l activity by chronic treatment with the FDA-approved potassium channel blocker 4-aminopyridine (4-AP

227 In this institutional review board-approved prospective study, a woman with triple-negative

228 included in this institutional review board-approved, prospective longitudinal study.

229 ols) according to institutional review board-approved protocols and shipped to a centralized biorepos

230 er of unexpected adverse events occurring in approved protocols, can be misleading indicators of part

231 were comparable to paired results from a CDC-approved quantitative RT-PCR (RT-qPCR) assay performed i

232 f Care Writing Groups drafted, reviewed, and approved recommendations, assigning to each recommendati

233 mes that AZI (1-g single dose) is used in an approved regimen that includes an additional antimicrobi

234 An Institutional Review Board approved retrospective search of University of Florida a

235 An IRB approved retrospective study of 140 patients with elevat

236 ty Act-compliant, institutional review board-approved retrospective study.

237 The only currently FDA-approved rexinoid, bexarotene, is ineffective as a singl

238 -stage or Food and Drug Administration (FDA)-approved small molecules to identify candidate therapeut

239 SRC inhibitor has been challenging, and FDA-approved SRC inhibitors, dasatinib and bosutinib, are mu

240 lenging and thus far there are no clinically approved strategies exploiting this cancer target.

241 This was an institutional review board-approved study of adult patients discharged with daptomy

242 In this institutional review board-approved study, a stroke database of 962 cases (mean pat

243 this prospective institutional review board-approved study, both MUSE DWI and single-shot DWI sequen

244 In this institutional review board approved-study, a total of 1830 posteroanterior radiogra

245 lanoma has poor overall survival (OS) and no approved systemic therapy options.

246 lopment of U.S. Food and Drug Administration-approved targeted therapies, such as TRK inhibitors for

247 eatment of cuSCC, which currently has no FDA-approved targeted therapies.See related commentary by Pa

248 te, there is no Food and Drug Administration-approved targeted therapy for advanced MCC.

249 he Ministry of Food and Drug Safety in Korea approved tenofovir disoproxil fumarate and emtricitabine

250 pment, the turnaround times, and the various approved tests, and compare them as regards the genes th

251 proteins and peptidomimetics that have been approved, that are undergoing phase I-III clinical trial

252 The Food and Drug Administration approved the first ICI, ipilimumab, in 2011 for the trea

253 ered on January 12th, 2018; Ethics Committee approved the study (ID: 1.790.088) on October 25th, 2016

254 monly encountered in bioactive compounds and approved therapeutic agents.

255 uxolitinib treatment offers the first widely approved therapeutic alternative for this post-hydroxyur

256 There is currently no approved therapeutic for human use against NiV infection

257 ighted in the efficient synthesis of the FDA-approved therapeutic lipopeptide tesamorelin and palmity

258 onalization of a natural product-derived FDA-approved therapeutic.

259 Lack of approved therapeutics often results in patients having a

260 No approved therapies exist for inoperable plexiform neurof

261 Furthermore, there are no approved therapies for COVID-19.

262 While there are currently no approved therapies for NASH, the bile acid-derived FXR a

263 spite an expanding global disease burden, no approved therapies or licensed vaccines exist.

264 causes explosive outbreaks but there are no approved therapies to treat or prevent CHIKV infection.

265 compounds, including a variety of clinically approved therapies.

266 While there is one FDA-approved therapy, it is associated with potential advers

267 r taken prior to starting a standard-of-care approved therapy.

268 This institutional review board approved this retrospective study, and waived the inform

269 DSW of different lines were sown as per the approved timings.

270 Medications approved to treat Alzheimer disease (donepezil, galantam

271 To date, no drug or vaccine has been approved to treat the severe disease caused by this coro

272 the sensitization of cancer cells to the FDA-approved topoisomerase inhibitors topotecan and irinotec

273 with a focus on trials conducted to support approved trastuzumab biosimilars.

274 There is no approved treatment for HMPV and only one prophylactic tr

275 Propranolol is an approved treatment for IHs, but its mechanism of action

276 There is no approved treatment for vitiligo repigmentation and curre

277 lergen-mediated inflammatory disease with no approved treatment in the United States.

278 With no approved treatment modalities for patients who progress

279 Despite the approved treatment options nintedanib and pirfenidone, t

280 Currently, there are no approved treatment options to control WNV infection.

281 Unfortunately, there is no FDA-approved treatment specific for chlamydial infections.

282 Most rare diseases still lack approved treatments despite major advances in research p

283 No approved treatments exist for age-related cognitive decl

284 There are currently no approved treatments or preventative therapeutic strategi

285 irus (HCV) infection, there are currently no approved treatments with direct-acting antiviral agents.

286 oor prognosis and accelerated death, with no approved treatments.

287 stinal stromal tumours who were resistant to approved treatments.

288 in the AGM model, these antimicrobials were approved under the Food and Drug Administration's Animal

289 echocardiography clinical practice committee approved use of EMW for patients with LQTS, making it a

290 of an effective subunit vaccine; however, no approved vaccine currently exists.

291 Food and Drug Administration (FDA)-approved vaccine labels.

292 The only currently U.S. FDA-approved vaccine to prevent anthrax in humans is anthrax

293 tly, treatments are limited, and there is no approved vaccine.

294 In the absence of approved vaccines and therapeutics for use in humans, Ni

295 date, no Food and Drug Administration (FDA)-approved vaccines are available to combat hemorrhagic fe

296 Currently, there are no FDA-approved vaccines or therapeutics available to combat VE

297 The study cohort comprised 57 FDA-approved vaccines.

298 Two repurposed FDA-approved VCP inhibitors abrogated VCP-mediated repressio

299 The proportion of drugs approved with an Orphan Drug Act designation increased f

300 se measures, such as the number of proposals approved with and without major modifications and the nu